Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference24 articles.
1. Prostate cancer clinical trial end points: “RECIST”ing a step backwards;Scher;Clin Cancer Res,2005
2. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials;Fleming;Nat Clin Pract Oncol,2006
3. Circulating tumor cells, disease progression, and survival in metastatic breast cancer;Cristofanilli;N Engl J Med,2004
4. The relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer;Cohen;J Clin Oncol,2008
5. Circulating tumor cells predict overall survival following treatment in metastatic prostate cancer;de Bono;Clin Cancer Res,2008
Cited by 543 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers;Frontiers in Oncology;2024-09-10
2. Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy;The Prostate;2024-09-06
3. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02
4. Fast and efficient isolation of murine circulating tumor cells using screencell technology for pre-clinical analyzes;Scientific Reports;2024-07-01
5. Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods;World Journal of Methodology;2024-06-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3